Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-25
2005-10-25
Jones, Dwayne (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S315000, C514S323000
Reexamination Certificate
active
06958351
ABSTRACT:
The invention provides new methods for treating certain disorders resulting from neurodegeneration and for treating depression which comprise administration of NR2B subunit selective NMDA antagonists. The disorders that can be treating by the invention include hearing loss, vision loss, neurodegeneration caused by epileptic seizures, neurotoxin poisoning, Restless Leg Syndrome, multi-system atrophy, non-vascular headache, and depression.
REFERENCES:
patent: 5710168 (1998-01-01), Chenard
patent: 6046213 (2000-04-01), Chenard et al.
patent: 0768086 (1997-04-01), None
patent: 0787493 (1997-08-01), None
patent: WO9707098 (1997-02-01), None
patent: WO 97/07098 (1997-02-01), None
patent: WO97/23202 (1997-07-01), None
patent: WO9723214 (1997-07-01), None
patent: WO9723215 (1997-07-01), None
patent: WO9723216 (1997-07-01), None
patent: WO9723458 (1997-07-01), None
patent: WO9944610 (1999-09-01), None
patent: WO9944640 (1999-09-01), None
patent: WO0000197 (2000-01-01), None
Stedman's Medical Dictionary, 25THEdition, Illustrated, pp. 1286 and 1287, 1994.
Hironaka, N., et al., Neuroscience Letters, vol. 288, No. 2, 2000, pp. 139-142, XP001077717.
Butler, T.W., et al., J. Med. Chem., vol. 41, 1998, pp. 1172-1184, XP001073767.
Menniti, Frank, et al., CP-101, 606, a potent neuroprotectant selective for forebrain neurons, European Journal of Pharmacology 331 (1997) pp. 117-126, XP-001150396.
Parsons, Chris G., et al., Glutamate in CNS Disorders as a Target for Drug Development: An Update, Drug News Perspect 11(9), Nov. 1998, pp. 523-569, XP-000910825.
Tamiz, Amir P., et al., Structure-Activity Relationships for a Series of Bis(phenylalkyl)amines: Potent Subtype—Selective Inhibitors of N-Methyl-D-aspartate Receptors, J. Med. Chem. 1998, 41, pp. 3499-3506, XP-001151638.
Taniguchi, Kana, et al., Antinoclceptive activity of CP-101, 606, an NMDA receptor NR2B subunit antagonist, British Journal of Pharmacology (1997) 122, pp. 809-812.
Boyce S., et al., Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn, Neuropharmacology 38, (1999) pp. 611-623, XP-001077718.
Albin, Roger L. and Sid Gilman, Autoradiographic localization of inhibitory and excitatory amino acid neurotransmitter receptors in human normal and olivopontocerebellar atrophy cerebellar cortex, Brain Research, 522 (1990) pp. 37-45, XP008016404.
Lagrze, Wolf A., N-methyl-D-aspartate receptor subunit mRNA expression in human retinal ganglion cells, Graefs Arch Clin Exp Ophthalmol (2000) 238: pp. 486-490, XP-001151637.
Dreyer, Evan B., et al., Greater sensitivity of larger retinal ganglion cells to NMDA-mediated cell death, NeuroReport 5, pp. 629-631 (1994), XP008016376.
Kapin, Michael A., et al., Neuroprotective Effects of Eliprodil in Retinal Excitoxity and Ischemia, IOVS, May 1999, vol. 40, No. 6, pp 1177-1182, XP008016405.
Chenard, B.L., et al., (1S,2S)-1-(4-Hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol: A Potent New Neuroproctectant Which Blocks N-Methyl-D-aspartate Responses, J. Med. Chem. 1995, 38, pp. 3138-3145, XP-000999280.
Menniti, Frank S., CP-101,606, an NR2B subunit selective NMDA receptor antagonist, inhibits NMDA and injury induced c-fos expression and cortical spreading depression in rodents, Neuropharmacology 39 (2000) pp. 1147-1155, XP-001074732.
Menniti Frank S., et al., CP-101,606: An NR2B-selective NMDA receptor antagonist, CNS Drug Reviews, vol. 4, No. 4, Jan. 1, 1998, pp. 307-322, XP008003933.
Chenard Bertrand L.
Menniti Frank S.
Saltarelli Mario
Dorigo Andrea E.
Jones Dwayne
Ling Lorraine B.
Pfizer Inc
Richardson Peter C.
LandOfFree
NMDA NR2B antagonists for treatment does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with NMDA NR2B antagonists for treatment, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NMDA NR2B antagonists for treatment will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3485222